Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 16:15 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
February 28, 2022 09:00 ET | Source: Throne Biotechnologies Inc

Throne Biotechnologies Launches Equity Crowdfunding to Support Phase 2 Clinical Trials in Type 1 Diabetes and Alopecia Areata

PARAMUS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies, one of the global-leading biotech companies aiming to find a cure for type 1 diabetes, announced the launch of their...
January 13, 2022 08:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Shares Updated Corporate Presentation

HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with...
December 06, 2021 17:19 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations

-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C.,...
November 09, 2021 08:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021, and provided an update on the...
October 28, 2021 14:30 ET | Source: SymbioCellTech, LLC

SymbioCellTech Demonstrates Preclinical Efficacy of Proprietary and Novel Human Neo-Islets™ Technology in STZ-Diabetic NOD-SCID Mice

SALT LAKE CITY, Oct. 28, 2021 (GLOBE NEWSWIRE) -- SymbioCellTech (SCT) announced today the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human...
October 12, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported...
August 04, 2021 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the...
May 05, 2021 16:10 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update

Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes Initiated two phase 1 clinical studies, mechanistic study of TTP399 and multiple ascending dose study of...
April 13, 2021 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes

HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...